induction phase1

Phase 3Small molecule

induction phase1 is one of 275 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

274

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaNot yet recruiting

Esophageal Squamous Cell CarcinomaRecruiting

Nasopharyngeal CarcinomaActive, not recruiting

Esophageal CancerRecruiting

Gastric CancerActive, not recruiting

Induction ChemotherapyRecruiting

Brain and Central Nervous System TumorsActive, not recruiting

TrialRecruiting

Esophageal Squamous CarcinomaActive, not recruiting

MedulloblastomaActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Not yet recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Esophageal CancerPhase 2

Recruiting

Gastric CancerPreclinical

Active, not recruiting

Induction ChemotherapyPhase 3

Recruiting

Brain and Central Nervous System TumorsPhase 2

Active, not recruiting

TrialPhase 3

Recruiting

Esophageal Squamous CarcinomaPhase 1

Active, not recruiting

MedulloblastomaPhase 3

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

181 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

44 2

Opdivo

Bristol-Myers Squibb

Phase 3

24 3

Camptosar

Pfizer

Phase 3

23 4

Keytruda

Merck & Co.

Phase 3

20 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

55 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

90 7

Taxotere

AAvyxa

Phase 3

45 8

Abraxane

Bristol-Myers Squibb

Phase 3

11 9

Avastin

Beyfortus

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Medulloblastoma

NCT02066220

Q3 2027

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT05062005

Q4 2028

N/ANot yet recruiting

Nasopharyngeal Carcinoma

NCT05622474

Q2 2029

Phase 2Active, not recruiting

Brain and Central Nervous System Tumors

NCT00602667

Phase 2Recruiting

Esophageal Squamous Cell Carcinoma

NCT06912074

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma5 trials

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT05304468·452 enrolled

Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05232552·37 enrolled

A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy

Not yet recruiting·SSun Yat-sen University·N/A·NCT05622474·236 enrolled

Show 2 more trials

Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

Unknown status·SShanghai Proton and Heavy Ion Center·Phase 2·NCT04143984·146 enrolled

ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma

Recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 3·NCT05062005·447 enrolled

Induction Chemotherapy3 trials

Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors

Terminated·MMemorial Sloan Kettering Cancer Center·N/A·NCT02519712·4 enrolled

Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study

Unknown status·FFeng Jing·Phase 2·NCT02187315·160 enrolled

Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

Recruiting·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT06207981·310 enrolled

Non-Small Cell Lung Cancer2 trials

Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 3·NCT01850303·632 enrolled

A Prospective Phase II Controlled Study to Evaluate the Impact of Thymosin Alpha 1 on the Completion Rate of Consolidation Immunotherapy After Radical Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer

Completed·SSun Yat-sen University·Phase 2·NCT06139419·114 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06912074·134 enrolled

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma: a Open-label, Randomized, Controlled Phase II Clinical Trial

Completed·SSun Yat-sen University·Phase 2·NCT06281886·170 enrolled

Lymphoblastic Lymphoma1 trial

Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

Unknown status·SSun Yat-sen University·Phase 2·NCT02396043·50 enrolled

18 more indications

Trial1 trial

Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC

Recruiting·—·Phase 3·NCT06846450·470 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Unknown status·—·Phase 3·NCT03815903·434 enrolled

Gastric Cancer1 trial

Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients

Completed·—··NCT02454647·46 enrolled

Breast Cancer1 trial

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT01491737·258 enrolled

Acute Myeloid Leukemia1 trial

Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)

Completed·SSeoul National University Hospital·Phase 2·NCT01247493·108 enrolled

Leukemia1 trial

A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Withdrawn· Eisai logo

Eisai·Phase 2·NCT00943553

Esophageal Squamous Carcinoma1 trial

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Active, not recruiting·SSun Yat-sen University·Phase 1·NCT06020885·18 enrolled

Surgery1 trial

A Study of Tongue Conservation Surgery for Oral Tongue Cancer

Terminated·TTaipei Veterans General Hospital, Taiwan·Phase 2·NCT03161548·23 enrolled

Infusion1 trial

Post Transplant Donor Lymphocyte Infusion

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00167180·57 enrolled

Myeloid Neoplasm1 trial

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Completed·HHospital Israelita Albert Einstein·Phase 2·NCT02084563·455 enrolled

Stage III1 trial

SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00002735·68 enrolled

Medulloblastoma1 trial

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Active, not recruiting·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2/3·NCT02066220·360 enrolled

Chemotherapy1 trial

Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04296747·100 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07259473·15 enrolled

Lung Cancer1 trial

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Terminated· Genmab logo

Genmab·Phase 2·NCT00460551·13 enrolled

Squamous Cell Carcinoma1 trial

Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma

Not yet recruiting·NNYU Langone Health·Phase 1/2·NCT07428148·60 enrolled

Brain and Central Nervous System Tumors1 trial

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT00602667·293 enrolled

Esophageal Cancer1 trial

PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer

Recruiting·MMedical College of Wisconsin·Phase 2·NCT06906887·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 31 trial records for induction phase1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — induction phase1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for induction phase1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Genmab

induction phase1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2028

Q2 2029

Trials by Indication[1]

Nasopharyngeal Carcinoma5 trials

Induction Chemotherapy3 trials

Non-Small Cell Lung Cancer2 trials

Esophageal Squamous Cell Carcinoma2 trials

Lymphoblastic Lymphoma1 trial

Trial1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Gastric Cancer1 trial

Breast Cancer1 trial

Acute Myeloid Leukemia1 trial

Leukemia1 trial

Esophageal Squamous Carcinoma1 trial

Surgery1 trial

Infusion1 trial

Myeloid Neoplasm1 trial

Stage III1 trial

Medulloblastoma1 trial

Chemotherapy1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Lung Cancer1 trial

Squamous Cell Carcinoma1 trial

Brain and Central Nervous System Tumors1 trial

Esophageal Cancer1 trial

References

Drug Info

Quick Facts

Related News